Schistosoma mansoni treatment reduces HIV entry into cervical CD4+ T cells and induces IFN-I pathways

Sergey Yegorov (), Vineet Joag, Ronald M. Galiwango, Sara V. Good, Juliet Mpendo, Egbert Tannich, Andrea K. Boggild, Noah Kiwanuka, Bernard S. Bagaya and Rupert Kaul
Additional contact information
Sergey Yegorov: University of Toronto
Vineet Joag: University of Toronto
Ronald M. Galiwango: University of Toronto
Sara V. Good: The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning
Juliet Mpendo: Uganda Virus Research Institute –International AIDS Vaccine Initiative HIV Vaccine Program
Egbert Tannich: Bernhard Nocht Institute for Tropical Medicine, National Reference Centre for Tropical Pathogens
Andrea K. Boggild: Department of Medicine, University Health Network
Noah Kiwanuka: Uganda Virus Research Institute –International AIDS Vaccine Initiative HIV Vaccine Program
Bernard S. Bagaya: Uganda Virus Research Institute –International AIDS Vaccine Initiative HIV Vaccine Program
Rupert Kaul: University of Toronto

Nature Communications, 2019, vol. 10, issue 1, 1-12

Abstract: Abstract Schistosoma mansoni (Sm) infection has been linked with an increased risk of HIV acquisition in women. Therefore, defining the mechanism(s) by which Sm alters HIV susceptibility might lead to new HIV prevention strategies. Here, we analyze the impact of standard Sm therapy in HIV-uninfected Sm+ Ugandan adult women on genital HIV susceptibility and mucosal and systemic immunology. Schistosomiasis treatment induces a profound reduction of HIV entry into cervical and blood CD4+ T cells that is sustained for up to two months, despite transient systemic and mucosal immune activation and elevated genital IL-1α levels. Genital IFN-α2a levels are also elevated post-treatment, and IFN-α2a blocks HIV entry into primary CD4+ T cells ex vivo. Transcriptomic analysis of blood mononuclear cells post-Sm treatment shows IFN-I pathway up-regulation and partial reversal of Sm-dysregulated interferon signaling. These findings indicate that Sm therapy may reduce HIV susceptibility for women with Sm infection, potentially through de-repression of IFN-I pathways.

Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-019-09900-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09900-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-09900-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().